Pfizer and Arvinas have collaborated to co-develop and co-commercialise ARV-471, an investigational oral Protac estrogen receptor protein degrader.
23 Jul 2021
21 Jul 2021
McKesson Corporation, Cardinal Health and Amerisource Bergen Drug, the three largest US drug distributors, have agreed to pay up to $1.18bn to settle the ongoing opioid-related case with the New York State and its participating subdivisions Nassau County and Suffolk County.
20 Jul 2021
Private equity firm Partners Group has agreed to acquire Pharmathen from an international investment firm BC Partners in a deal valued about $1.88bn (€1.6bn).
19 Jul 2021
GlaxoSmithKline (GSK) has announced plans to construct a new campus for biotechnology and early-stage life science companies in Stevenage, England.
16 Jul 2021
Regeneron has announced plans to invest about $1.8bn to expand its facilities at its Westchester County campus in the US, over the next six years.
13 Jul 2021
Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn.
08 Jul 2021
Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.
07 Jul 2021
Eureka Therapeutics and Memorial Sloan Kettering Cancer Center (MSK) have signed a new G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) license agreement with Sanofi to target multiple myeloma.
05 Jul 2021
GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases.
30 Jun 2021
Global biopharmaceutical firm Sanofi has launched a dedicated vaccines mRNA Center of Excellence to accelerate development and delivery of next-generation vaccines.